This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thermo Fisher (TMO) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Strong analytical instruments business, product portfolio expansion and prudent growth strategy are likely to support Thermo Fisher (TMO) in Q1. However, forex might act as a dampener.
What's in Store for Align Technology (ALGN) in Q1 Earnings?
by Zacks Equity Research
Higher Invisalign case volume, solid show by Clear Aligner segment and anticipated sturdy growth at Scanner and Service business are likely to support Align Technology (ALGN) in Q1. However, operating expenses are likely to act as dampeners.
Varian Medical (VAR) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Varian Medical (VAR) expects to gain significantly from APAC and EMEA regions in fiscal Q2.
What's in Store for Edwards Lifesciences' (EW) Q1 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) expects to gain from core Critical Care product group in Q1.
UnitedHealth (UNH) Q1 Earnings Beat Estimates, Guides Up
by Zacks Equity Research
UnitedHealth (UNH) Q1 earnings beat on higher revenues and membership.
Cardinal Health (CAH) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Cardinal Health (CAH) closed at $46.79 in the latest trading session, marking a +0.88% move from the prior day.
What's in the Store for UnitedHealth (UNH) Earnings in Q1?
by Zacks Equity Research
UnitedHealth (UNH) should gain from higher revenues, membership partly offset by rise in expenses.
Top Ranked Income Stocks to Buy for April 4th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, April 4th
Will Cardinal (CAH) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Can Retail Pharmacy USA Lift Walgreens' (WBA) Q2 Earnings?
by Zacks Equity Research
Widening pharmacy network, healthy prescription volumes along with contributions from Rite Aid are expected to contribute to Walgreens Boots' (WBA) top line in the fiscal second quarter.
CAH or ALGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CAH vs. ALGN: Which Stock Is the Better Value Option?
Is Cardinal Health (CAH) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Cardinal Health (CAH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (CAH) Outperforming Other Medical Stocks This Year?
Top Ranked Income Stocks to Buy for March 19th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, March 19th
Is Cardinal Health (CAH) a Solid Pick for Value Investors?
by Zacks Equity Research
Let's see if Cardinal Health (CAH) stock is a good choice for value-oriented investors right now from multiple angles.
CAH vs. ALGN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CAH vs. ALGN: Which Stock Is the Better Value Option?
Why Is Cardinal (CAH) Down 12.1% Since Last Earnings Report?
by Zacks Equity Research
Cardinal (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Cardinal Health (CAH) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Top Ranked Income Stocks to Buy for March 6th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, March 6th
Here's Why You Should Hold Becton, Dickinson Stock for Now
by Zacks Equity Research
Becton, Dickinson's (BDX) MAX enteric viral panel receives FDA clearance.
Cardinal Health Strong on Pharmaceutical, Competition Rife
by Zacks Equity Research
Cardinal Health (CAH) is on track to deliver targeted annualized cost savings of $100 million in fiscal 2019.
Company News For Feb 8, 2019
by Zacks Equity Research
Companies In The News Are: CMG,SPB,HBI,CAH
Cardinal Health (CAH) Surges: Stock Moves 6.8% Higher
by Zacks Equity Research
Cardinal Health (CAH) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Cardinal Health (CAH) Beats on Q2 Earnings, Ups FY19 View
by Zacks Equity Research
Cardinal Health's (CAH) Q2 results benefit from strong sales in the Pharmaceutical segment. An upbeat guidance is indicative of brighter prospects.
Cardinal Health (CAH) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 18.35% and 4.10%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?